NeoGenomics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
NeoGenomics, Inc. (NEO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $10.80 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-28
- NeoGenomics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $10.86, a 13.40% decline year-over-year.
- NeoGenomics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $12.54, a 23.49% decline year-over-year.
- NeoGenomics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $16.39, a 54.33% increase year-over-year.
- NeoGenomics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $10.62, a 57.57% decline year-over-year.
- NeoGenomics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $11.58, a 22.85% decline from fiscal 2024.
- NeoGenomics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $15.01, a 12.27% decline from fiscal 2023.
- NeoGenomics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $17.11, a 18.08% increase from fiscal 2022.
- NeoGenomics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $14.49, a 65.61% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $10.80 10-Q · filed 2026-07-28 | ||||
| 2026-03-31 | $10.86 10-Q · filed 2026-04-28 | ||||
| 2025-12-31 | $11.58 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | $11.56 10-Q · filed 2025-10-28 | ||||
| 2025-06-30 | $11.66 10-Q · filed 2025-07-29 | ||||
| 2025-03-31 | $12.54 10-Q · filed 2025-04-29 | ||||
| 2024-12-31 | $15.01 10-K · filed 2026-02-17 | ||||
| 2024-09-30 | $14.99 10-Q · filed 2024-11-05 | ||||
| 2024-06-30 | $14.91 10-Q · filed 2024-07-30 | ||||
| 2024-03-31 | $16.39 10-Q · filed 2024-04-30 | ||||
| 2023-12-31 | $17.11 10-K · filed 2026-02-17 | ||||
| 2023-09-30 | $17.17 10-Q · filed 2023-11-06 | ||||
| 2023-06-30 | $17.34 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $10.62 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $14.49 10-K · filed 2025-02-18 | ||||
| 2022-09-30 | $14.94 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $15.80 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $25.03 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $42.13 10-K · filed 2024-02-20 | ||||
| 2021-09-30 | $48.19 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $49.04 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $53.16 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | $28.33 10-K · filed 2023-02-24 | ||||
| 2020-09-30 | $28.33 10-Q · filed 2020-10-29 | ||||
| 2020-06-30 | $28.09 10-Q · filed 2020-07-31 | ||||
| 2020-03-31 | $28.36 10-Q · filed 2020-04-29 | ||||
| 2019-12-31 | $19.70 10-K · filed 2022-02-25 | ||||
| 2019-09-30 | $19.74 10-Q · filed 2019-11-13 | ||||
| 2019-06-30 | $19.65 10-Q · filed 2019-08-07 | ||||
| 2019-03-31 | $19.12 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | $9.03 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $8.42 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $8.34 10-Q · filed 2018-08-06 | ||||
| 2018-03-31 | $8.06 10-Q · filed 2018-05-08 | ||||
| 2017-12-31 | $7.60 10-K · filed 2020-02-28 | ||||
| 2017-09-30 | $7.56 10-Q · filed 2017-11-13 | ||||
| 2017-06-30 | $7.54 10-Q · filed 2017-08-07 | ||||
| 2017-03-31 | $8.52 10-Q · filed 2017-05-09 | ||||
| 2016-12-31 | $7.14 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $7.10 10-Q · filed 2016-11-07 | ||||
| 2016-06-30 | $6.77 10-Q · filed 2016-08-05 | ||||
| 2016-03-31 | $6.77 10-Q · filed 2016-05-10 | ||||
| 2015-12-31 | $4.90 10-K · filed 2018-03-13 | ||||
| 2015-09-30 | $4.80 10-Q · filed 2015-11-06 | ||||
| 2015-06-30 | $4.77 10-Q · filed 2015-07-31 | ||||
| 2015-03-31 | $4.10 10-Q · filed 2015-05-11 | ||||
| 2014-12-31 | $4.21 10-K · filed 2017-03-14 | ||||
| 2013-12-31 | $3.66 10-K · filed 2016-04-18 | ||||
| 2012-12-31 | $1.64 10-K · filed 2015-03-03 | $0.73 10-K · filed 2013-02-21 | |||
| 2011-12-31 | $1.39 10-K · filed 2014-02-24 | $0.51 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |